These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23119007)

  • 1. The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.
    Li SC; Martijn C; Cui T; Essaghir A; Luque RM; Demoulin JB; Castaño JP; Öberg K; Giandomenico V
    PLoS One; 2012; 7(10):e48411. PubMed ID: 23119007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells.
    van Adrichem RC; de Herder WW; Kamp K; Brugts MP; de Krijger RR; Sprij-Mooij DM; Lamberts SW; van Koetsveld PM; Janssen JA; Hofland LJ
    Neuroendocrinology; 2016; 103(6):815-25. PubMed ID: 26836610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
    Kaltsas GA; Papadogias D; Makras P; Grossman AB
    Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated miR-16-5p induces somatostatin receptor 2 expression in neuroendocrine tumor cells.
    Jo H; Park Y; Kim J; Kwon H; Kim T; Lee J; Pyun JC; Lee M; Yun M
    PLoS One; 2020; 15(10):e0240107. PubMed ID: 33045023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
    Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
    Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt/β-catenin modulating drugs regulate somatostatin receptor expression and internalization of radiolabelled octreotide in neuroendocrine tumor cells.
    Weich A; Rogoll D; Peschka M; Weich W; Pongracz J; Brand M; Fröhlich M; Serfling SE; Rowe SP; Kosmala A; Reiter FP; Meining A; Werner RA; Scheurlen M
    Nucl Med Commun; 2023 Apr; 44(4):259-269. PubMed ID: 36804512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.
    Kidd M; Drozdov I; Joseph R; Pfragner R; Culler M; Modlin I
    Cancer; 2008 Aug; 113(4):690-700. PubMed ID: 18618499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Evaluation of Response to Octreotide and Chemotherapy in High-Grade Malignant Neuroendocrine Tumors and Promising In Vitro Preclinical Results with Pasireotide.
    Doello K; Chico MA; Quiñonero F; Ortiz R; Prados J; Mesas C; Melguizo C
    Medicina (Kaunas); 2024 Jun; 60(7):. PubMed ID: 39064468
    [No Abstract]   [Full Text] [Related]  

  • 10. Somatostatin receptor subtypes in neuroendocrine tumor cell lines and tumor tissues.
    Jonas S; John M; Boese-Landgraf J; Häring R; Prevost G; Thomas F; Rosewicz S; Riecken EO; Wiedenmann B; Neuhaus P
    Langenbecks Arch Chir; 1995; 380(2):90-5. PubMed ID: 7760656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization.
    Heidari P; Wehrenberg-Klee E; Habibollahi P; Yokell D; Kulke M; Mahmood U
    Cancer Res; 2013 Dec; 73(23):6865-73. PubMed ID: 24080280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of endothelial proliferation by the somatostatin analogue SOM230.
    Adams RL; Adams IP; Lindow SW; Atkin SL
    Clin Endocrinol (Oxf); 2004 Oct; 61(4):431-6. PubMed ID: 15473874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Somatostatin Signalling in Neuroendocrine Tumours.
    Rogoza O; Megnis K; Kudrjavceva M; Gerina-Berzina A; Rovite V
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
    Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
    Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling.
    Ungefroren H; Künstner A; Busch H; Franzenburg S; Luley K; Viol F; Schrader J; Konukiewitz B; Wellner UF; Meyhöfer SM; Keck T; Marquardt JU; Lehnert H
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
    Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
    Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer: antitumor effects of octreotide LAR, a somatostatin analog.
    Oberg K
    Nat Rev Endocrinol; 2010 Apr; 6(4):188-9. PubMed ID: 20336162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
    Herrera-Martínez AD; van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Culler MD; de Herder WW; Luque RM; Feelders RA; Hofland LJ
    Endocr Relat Cancer; 2019 Jun; 26(6):585-599. PubMed ID: 30939452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine tumors in the brain.
    Cavalla P; Schiffer D
    Ann Oncol; 2001; 12 Suppl 2():S131-4. PubMed ID: 11762340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.